All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cetuximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
chimeric origin	4954	205923-56-4

Description:

Molecule	Description
Synonyms: cetuximab cetuximab (genetical recombination) erbitux C-225 IMC-C225	A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 29, 2004	EMA
Feb. 12, 2004	FDA	IMCLONE
July 16, 2008	PMDA	Merck

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	466.94	22.69	122	12454	4874	63471572
Diarrhoea	208.50	22.69	444	12132	714922	62761524
Mucosal inflammation	191.62	22.69	118	12458	46810	63429636
Neutropenia	186.28	22.69	200	12376	174805	63301641
Malignant neoplasm progression	176.07	22.69	139	12437	81982	63394464
Dehydration	168.63	22.69	189	12387	173165	63303281
Paronychia	145.76	22.69	51	12525	5514	63470932
Hypomagnesaemia	134.70	22.69	79	12497	28658	63447788
Skin toxicity	122.68	22.69	43	12533	4671	63471775
Disease progression	114.38	22.69	131	12445	122627	63353819
Rash	111.56	22.69	301	12275	560570	62915876
Vomiting	108.96	22.69	298	12278	559319	62917127
Drug ineffective	100.68	22.69	41	12535	1044724	62431722
Serous retinal detachment	92.43	22.69	20	12556	347	63476099
Nausea	83.97	22.69	362	12214	854109	62622337
Palmar-plantar erythrodysaesthesia syndrome	79.23	22.69	52	12524	22963	63453483
Pulmonary embolism	78.83	22.69	106	12470	116578	63359868
Radiation skin injury	73.67	22.69	20	12556	923	63475523
Skin fissures	66.02	22.69	36	12540	11352	63465094
Hypokalaemia	65.12	22.69	91	12485	103713	63372733
Dermatitis	64.99	22.69	41	12535	16917	63459529
Stomatitis	60.80	22.69	103	12473	138622	63337824
Arthralgia	60.35	22.69	19	12557	569691	62906755
Infusion related reaction	58.06	22.69	141	12435	245380	63231066
Pyrexia	54.35	22.69	210	12366	470268	63006178
Metastases to lung	49.29	22.69	31	12545	12719	63463727
Interstitial lung disease	49.22	22.69	61	12515	61847	63414599
Anaemia	45.98	22.69	145	12431	293285	63183161
Thrombocytopenia	45.97	22.69	96	12480	151061	63325385
Rash pustular	44.94	22.69	24	12552	7258	63469188
Haematotoxicity	44.50	22.69	26	12550	9350	63467096
Chills	44.22	22.69	80	12496	113298	63363148
Febrile neutropenia	44.21	22.69	82	12494	118367	63358079
Decreased appetite	43.95	22.69	129	12447	250923	63225523
Neoplasm progression	41.02	22.69	43	12533	36385	63440061
Abdominal discomfort	39.10	22.69	8	12568	320877	63155569
Deep vein thrombosis	39.06	22.69	64	12512	83736	63392710
Colorectal cancer metastatic	38.70	22.69	11	12565	602	63475844
Nasopharyngitis	36.32	22.69	4	12572	254253	63222193
Ileus	36.03	22.69	27	12549	14698	63461748
Skin reaction	35.82	22.69	27	12549	14822	63461624
Weight increased	35.07	22.69	5	12571	260787	63215659
Drug intolerance	35.01	22.69	9	12567	308652	63167794
Neurotoxicity	34.71	22.69	28	12548	16962	63459484
Dry skin	34.35	22.69	49	12527	56838	63419608
Neutrophil count decreased	33.20	22.69	48	12528	56358	63420088
Hypertrichosis	31.84	22.69	11	12565	1143	63475303
Sinusitis	31.29	22.69	4	12572	226649	63249797
Sepsis	31.00	22.69	83	12493	153040	63323406
Neuropathy peripheral	30.88	22.69	69	12507	113598	63362848
Leukopenia	30.71	22.69	55	12521	77235	63399211
Asthenia	30.31	22.69	153	12423	383451	63092995
Drug hypersensitivity	30.02	22.69	12	12564	310675	63165771
Dyspnoea	29.73	22.69	228	12348	661085	62815361
Renal tubular disorder	29.10	22.69	13	12563	2669	63473777
Multiple-drug resistance	29.01	22.69	16	12560	5154	63471292
Trichomegaly	28.93	22.69	6	12570	84	63476362
Therapeutic product effect decreased	27.68	22.69	3	12573	193184	63283262
Anastomotic leak	27.61	22.69	8	12568	469	63475977
Pain	27.45	22.69	67	12509	740561	62735885
Acne	27.12	22.69	28	12548	23265	63453181
Stress cardiomyopathy	26.92	22.69	19	12557	9431	63467015
Metastases to liver	26.78	22.69	28	12548	23611	63452835
Bone marrow failure	26.78	22.69	31	12545	29259	63447187
Dysphagia	26.59	22.69	56	12520	88529	63387917
Hypocalcaemia	26.41	22.69	32	12544	31681	63444765
Product dose omission issue	26.23	22.69	7	12569	234306	63242140
Endothelial dysfunction	25.31	22.69	6	12570	159	63476287
Abdominal pain	24.54	22.69	119	12457	293337	63183109
Anaphylactic reaction	23.69	22.69	45	12531	66055	63410391
Haemolytic uraemic syndrome	23.59	22.69	11	12565	2492	63473954
Drug interaction	23.56	22.69	8	12568	229123	63247323
Chemical burns of eye	23.20	22.69	5	12571	85	63476361
Swelling	22.97	22.69	13	12563	275365	63201081

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	900.33	18.41	283	24659	5906	34926083
Infusion related reaction	439.44	18.41	337	24605	52720	34879269
Mucosal inflammation	423.86	18.41	291	24651	38331	34893658
Hypomagnesaemia	298.76	18.41	189	24753	21662	34910327
Rash	292.31	18.41	548	24394	222204	34709785
Skin toxicity	286.12	18.41	113	24829	4671	34927318
Anaphylactic reaction	284.43	18.41	213	24729	32088	34899901
Dehydration	266.17	18.41	391	24551	129578	34802411
Radiation skin injury	257.67	18.41	67	24875	678	34931311
Paronychia	234.07	18.41	89	24853	3316	34928673
Stomatitis	195.00	18.41	193	24749	42321	34889668
Malignant neoplasm progression	172.91	18.41	260	24682	87786	34844203
Neutropenia	139.83	18.41	330	24612	156448	34775541
Dysphagia	120.62	18.41	183	24759	62198	34869791
Serous retinal detachment	118.90	18.41	35	24907	577	34931412
Drug ineffective	117.37	18.41	93	24849	456658	34475331
Chills	111.44	18.41	204	24738	80839	34851150
Hypotension	108.75	18.41	376	24566	221273	34710716
Palmar-plantar erythrodysaesthesia syndrome	107.63	18.41	92	24850	16703	34915286
Hypersensitivity	101.32	18.41	167	24775	60868	34871121
Diarrhoea	99.76	18.41	543	24399	389369	34542620
Acne	99.58	18.41	74	24868	10992	34920997
Pharyngeal inflammation	96.02	18.41	26	24916	311	34931678
Drug interaction	86.33	18.41	27	24915	225919	34706070
Vomiting	83.18	18.41	373	24569	247248	34684741
Flushing	78.63	18.41	106	24836	32314	34899675
Decreased appetite	74.37	18.41	274	24668	166118	34765871
Disease progression	72.88	18.41	205	24737	107872	34824117
Nausea	72.82	18.41	452	24490	339456	34592533
Erythema	72.66	18.41	181	24761	88599	34843390
Dermatitis	69.24	18.41	56	24886	9412	34922577
Skin reaction	68.33	18.41	44	24898	5186	34926803
Conjunctivitis	68.03	18.41	56	24886	9649	34922340
Skin fissures	65.65	18.41	43	24899	5216	34926773
Rash pustular	64.56	18.41	43	24899	5365	34926624
Arthralgia	61.96	18.41	22	24920	170019	34761970
Product dose omission issue	58.59	18.41	8	24934	119703	34812286
Folliculitis	56.19	18.41	37	24905	4529	34927460
Hypocalcaemia	55.24	18.41	77	24865	24212	34907777
Radiation mucositis	53.49	18.41	15	24927	206	34931783
Pyrexia	51.33	18.41	409	24533	332604	34599385
Fall	51.00	18.41	42	24900	202843	34729146
Toxicity to various agents	50.96	18.41	41	24901	200321	34731668
Pulmonary embolism	50.74	18.41	160	24782	89586	34842403
Device related infection	50.64	18.41	62	24880	17175	34914814
Condition aggravated	50.56	18.41	38	24904	192158	34739831
Neoplasm progression	50.22	18.41	72	24870	23228	34908761
Pain in extremity	48.46	18.41	15	24927	126498	34805491
Pulse absent	48.20	18.41	37	24905	5766	34926223
Oxygen saturation decreased	47.48	18.41	113	24829	53705	34878284
Anaphylactic shock	46.28	18.41	57	24885	15884	34916105
Dyspnoea	46.21	18.41	440	24502	376342	34555647
Neuropathy peripheral	45.74	18.41	147	24795	83116	34848873
Thrombocytopenia	43.34	18.41	223	24719	156024	34775965
Ileus	43.15	18.41	56	24886	16443	34915546
Neutrophil count decreased	42.61	18.41	105	24837	50999	34880990
Leukopenia	42.08	18.41	119	24823	62737	34869252
Interstitial lung disease	41.20	18.41	121	24821	65161	34866828
Pneumatosis intestinalis	39.29	18.41	28	24914	3895	34928094
Pruritus	38.92	18.41	202	24740	141779	34790210
Insomnia	38.58	18.41	13	24929	103894	34828095
Onycholysis	38.46	18.41	16	24926	756	34931233
COVID-19	38.36	18.41	5	24937	77545	34854444
Cardio-respiratory arrest	38.33	18.41	106	24836	55167	34876822
Gastrointestinal toxicity	38.32	18.41	24	24918	2695	34929294
Gait disturbance	36.59	18.41	8	24934	85132	34846857
Proteus infection	35.99	18.41	17	24925	1089	34930900
Dry skin	35.87	18.41	73	24869	31214	34900775
Blood pressure immeasurable	35.71	18.41	16	24926	907	34931082
Weight increased	35.67	18.41	11	24931	93022	34838967
Blood magnesium decreased	34.79	18.41	32	24910	6391	34925598
Clostridial infection	34.30	18.41	25	24917	3602	34928387
Tumour haemorrhage	34.03	18.41	23	24919	2939	34929050
Nasopharyngitis	33.46	18.41	5	24937	69963	34862026
Urticaria	33.22	18.41	109	24833	62268	34869721
Peripheral swelling	31.29	18.41	8	24934	76533	34855456
Blood pressure decreased	31.09	18.41	94	24848	51421	34880568
Alopecia	30.53	18.41	59	24883	24296	34907693
Hospitalisation	29.81	18.41	3	24939	56899	34875090
Nail dystrophy	29.73	18.41	10	24932	259	34931730
Febrile neutropenia	29.12	18.41	182	24760	136667	34795322
Metastases to liver	29.11	18.41	42	24900	13621	34918368
Necrotising oesophagitis	29.11	18.41	12	24930	554	34931435
White blood cell count decreased	29.10	18.41	140	24802	95305	34836684
Oesophagitis	28.60	18.41	41	24901	13220	34918769
Headache	28.57	18.41	63	24879	200572	34731417
Nail disorder	28.42	18.41	18	24924	2061	34929928
Abdominal discomfort	27.00	18.41	5	24937	59830	34872159
Anxiety	26.97	18.41	19	24923	99409	34832580
Prothrombin level decreased	26.80	18.41	14	24928	1114	34930875
Cardiac failure congestive	26.70	18.41	13	24929	83257	34848732
Monocytopenia	26.30	18.41	7	24935	78	34931911
Laryngeal oedema	26.18	18.41	21	24921	3487	34928502
Induration	25.76	18.41	13	24929	962	34931027
Product use in unapproved indication	25.19	18.41	28	24914	117471	34814518
Influenza	25.05	18.41	3	24939	49663	34882326
Metastases to lung	24.94	18.41	32	24910	9288	34922701
Lymphopenia	24.81	18.41	43	24899	16292	34915697
Coronary artery disease	24.16	18.41	3	24939	48302	34883687
Hypophagia	24.00	18.41	53	24889	23969	34908020
Aspiration	23.84	18.41	36	24906	12158	34919831
Hypokalaemia	23.55	18.41	93	24849	58121	34873868
Depression	23.26	18.41	21	24921	97077	34834912
Joint swelling	23.09	18.41	7	24935	59883	34872106
Embolism	22.73	18.41	28	24914	7801	34924188
Pneumonitis	22.52	18.41	64	24878	33814	34898175
Unresponsive to stimuli	22.29	18.41	56	24886	27513	34904476
Anaphylactoid reaction	21.93	18.41	16	24926	2309	34929680
Enteritis	21.86	18.41	28	24914	8114	34923875
Neurotoxicity	21.81	18.41	43	24899	17967	34914022
Hypovolaemic shock	21.64	18.41	26	24916	7059	34924930
Odynophagia	21.53	18.41	23	24919	5498	34926491
Overdose	21.45	18.41	20	24922	91039	34840950
Bronchospasm	21.43	18.41	32	24910	10699	34921290
Inappropriate schedule of product administration	21.10	18.41	9	24933	62287	34869702
Pelvic sepsis	20.94	18.41	4	24938	7	34931982
Memory impairment	20.93	18.41	3	24939	43315	34888674
Musculoskeletal stiffness	20.85	18.41	4	24938	46676	34885313
Cerebral ischaemia	20.64	18.41	24	24918	6298	34925691
Myalgia	20.37	18.41	18	24924	84092	34847897
Abdominal compartment syndrome	20.30	18.41	11	24931	942	34931047
Butterfly rash	20.21	18.41	6	24936	102	34931887
Loss of consciousness	20.16	18.41	114	24828	82553	34849436
Cyanosis	19.91	18.41	34	24908	12730	34919259
Intentional product use issue	19.69	18.41	9	24933	59807	34872182
Ileal perforation	19.62	18.41	10	24932	756	34931233
Pneumonia aspiration	19.48	18.41	70	24872	41833	34890156
Muscle spasms	19.47	18.41	15	24927	74986	34857003
Mucosal infection	19.41	18.41	7	24935	224	34931765
Balance disorder	19.21	18.41	3	24939	40651	34891338
Bone marrow failure	19.19	18.41	55	24887	29198	34902791
Suicidal ideation	19.04	18.41	3	24939	40385	34891604
Metastases to lymph nodes	18.98	18.41	20	24922	4708	34927281
Diabetes mellitus	18.96	18.41	5	24937	46868	34885121
Myelosuppression	18.67	18.41	42	24900	19223	34912766
Haematotoxicity	18.65	18.41	26	24916	8168	34923821
Stridor	18.55	18.41	15	24927	2519	34929470

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dermatitis acneiform	1221.75	18.89	352	32323	9641	79702072
Mucosal inflammation	445.55	18.89	314	32361	75266	79636447
Hypomagnesaemia	421.72	18.89	254	32421	46657	79665056
Skin toxicity	395.11	18.89	143	32532	8171	79703542
Dehydration	351.70	18.89	469	32206	247718	79463995
Paronychia	351.34	18.89	129	32546	7679	79704034
Neutropenia	326.68	18.89	489	32186	287221	79424492
Malignant neoplasm progression	322.83	18.89	335	32340	135655	79576058
Radiation skin injury	303.98	18.89	78	32597	1356	79710357
Diarrhoea	263.31	18.89	873	31802	879616	78832097
Infusion related reaction	232.53	18.89	371	32304	229866	79481847
Anaphylactic reaction	227.36	18.89	222	32453	83521	79628192
Rash	214.56	18.89	619	32056	577739	79133974
Serous retinal detachment	208.25	18.89	54	32621	980	79710733
Stomatitis	185.85	18.89	263	32412	146494	79565219
Palmar-plantar erythrodysaesthesia syndrome	179.75	18.89	131	32544	33003	79678710
Disease progression	159.08	18.89	277	32398	184085	79527628
Chills	158.57	18.89	256	32419	159978	79551735
Drug ineffective	155.06	18.89	130	32545	1080783	78630930
Arthralgia	141.23	18.89	31	32644	571772	79139941
Dysphagia	128.86	18.89	201	32474	121935	79589778
Vomiting	121.95	18.89	567	32108	665261	79046452
Decreased appetite	117.44	18.89	357	32318	342061	79369652
Thrombocytopenia	110.79	18.89	297	32378	264962	79446751
Skin fissures	110.22	18.89	68	32607	13005	79698708
Dermatitis	108.20	18.89	81	32594	21240	79690473
Pulmonary embolism	107.34	18.89	225	32450	171429	79540284
Neuropathy peripheral	106.13	18.89	200	32475	141105	79570608
Interstitial lung disease	106.04	18.89	176	32499	112424	79599289
Pharyngeal inflammation	102.63	18.89	31	32644	999	79710714
Pyrexia	92.85	18.89	533	32142	678176	79033537
Joint swelling	91.67	18.89	7	32668	288639	79423074
Nausea	91.08	18.89	686	31989	956510	78755203
Drug interaction	90.12	18.89	29	32646	415154	79296559
Leukopenia	90.08	18.89	167	32508	116346	79595367
Rash pustular	88.22	18.89	56	32619	11255	79700458
Hypotension	87.88	18.89	385	32290	439932	79271781
Metastases to lung	85.54	18.89	66	32609	18097	79693616
Peripheral swelling	81.63	18.89	8	32667	269609	79442104
Hypocalcaemia	80.84	18.89	101	32574	49823	79661890
Neoplasm progression	79.63	18.89	102	32573	51580	79660133
Acne	79.22	18.89	75	32600	27115	79684598
Condition aggravated	78.23	18.89	55	32620	501069	79210644
Febrile neutropenia	77.35	18.89	239	32436	230760	79480953
Skin reaction	77.01	18.89	59	32616	16009	79695704
Nasopharyngitis	75.65	18.89	8	32667	253873	79457840
Ileus	73.89	18.89	71	32604	26140	79685573
Fall	72.89	18.89	56	32619	487573	79224140
Hypokalaemia	71.19	18.89	172	32503	143868	79567845
Weight increased	70.49	18.89	14	32661	277372	79434341
Neutrophil count decreased	68.05	18.89	131	32544	93828	79617885
Headache	66.85	18.89	103	32572	653669	79058044
Product dose omission issue	66.12	18.89	11	32664	247526	79464187
Conjunctivitis	65.68	18.89	66	32609	25649	79686064
Metastases to liver	63.90	18.89	68	32607	28246	79683467
Pain in extremity	63.78	18.89	35	32640	364503	79347210
Dry skin	63.59	18.89	106	32569	67889	79643824
Abdominal discomfort	62.98	18.89	13	32662	250714	79460999
Flushing	60.20	18.89	120	32555	88148	79623565
Erythema	58.71	18.89	213	32462	223077	79488636
Pulse absent	57.17	18.89	41	32634	10062	79701651
Anaemia	56.46	18.89	343	32332	444672	79267041
Radiation mucositis	54.90	18.89	14	32661	237	79711476
Therapeutic product effect decreased	54.88	18.89	3	32672	163860	79547853
Drug intolerance	54.57	18.89	20	32655	264099	79447614
Drug abuse	54.42	18.89	3	32672	162688	79549025
Musculoskeletal stiffness	53.46	18.89	5	32670	175003	79536710
Device related infection	53.32	18.89	68	32607	34226	79677487
Tumour haemorrhage	52.19	18.89	28	32647	4116	79707597
Sepsis	50.18	18.89	231	32444	269197	79442516
Sinusitis	49.37	18.89	10	32665	195491	79516222
White blood cell count decreased	48.96	18.89	179	32496	188109	79523604
Pain	48.28	18.89	139	32536	703663	79008050
Haematotoxicity	47.49	18.89	44	32631	15475	79696238
Toxicity to various agents	47.39	18.89	62	32613	421478	79290235
Onycholysis	47.12	18.89	21	32654	2062	79709651
Dyspnoea	46.74	18.89	546	32129	856479	78855234
Enteritis	45.90	18.89	42	32633	14541	79697172
Neurotoxicity	45.16	18.89	61	32614	32457	79679256
Contraindicated product administered	44.35	18.89	6	32669	157532	79554181
Gait disturbance	44.08	18.89	15	32660	207491	79504222
Colorectal cancer metastatic	43.21	18.89	17	32658	1221	79710492
Insomnia	42.19	18.89	24	32651	245146	79466567
Hypersensitivity	40.37	18.89	213	32462	262026	79449687
Hepatic enzyme increased	39.13	18.89	13	32662	182597	79529116
Oesophagitis	39.08	18.89	49	32626	24240	79687473
Drug hypersensitivity	38.96	18.89	39	32636	298877	79412836
Contusion	38.86	18.89	7	32668	148769	79562944
Pneumatosis intestinalis	38.60	18.89	27	32648	6370	79705343
Deep vein thrombosis	38.47	18.89	123	32552	120796	79590917
Asthma	38.37	18.89	5	32670	135090	79576623
Blood pressure immeasurable	37.56	18.89	18	32657	2086	79709627
Discomfort	37.29	18.89	4	32671	125613	79586100
Gastrointestinal toxicity	37.16	18.89	29	32646	8080	79703633
Influenza	36.33	18.89	5	32670	129601	79582112
Blood magnesium decreased	36.10	18.89	39	32636	16473	79695240
Proteus infection	34.45	18.89	17	32658	2101	79709612
Subileus	34.43	18.89	24	32651	5630	79706083
Clostridial infection	34.21	18.89	24	32651	5690	79706023
Product use issue	34.05	18.89	22	32653	209800	79501913
Wound	33.73	18.89	4	32671	116175	79595538
Pneumonitis	33.67	18.89	76	32599	60784	79650929
Intentional product use issue	32.29	18.89	11	32664	152101	79559612
Nail dystrophy	32.19	18.89	13	32662	1000	79710713
Swelling	32.17	18.89	25	32650	216686	79495027
Anaphylactic shock	32.16	18.89	55	32620	35941	79675772
Glossodynia	31.42	18.89	3	32672	103334	79608379
Oxygen saturation decreased	31.29	18.89	120	32555	128927	79582786
Intestinal obstruction	31.15	18.89	60	32615	42960	79668753
Pneumonia aspiration	30.97	18.89	78	32597	66889	79644824
Cerebral ischaemia	30.94	18.89	30	32645	11165	79700548
COVID-19	30.80	18.89	13	32662	157661	79554052
Laryngeal oedema	30.77	18.89	26	32649	8103	79703610
Bone marrow failure	30.74	18.89	66	32609	51041	79660672
Bronchospasm	30.58	18.89	44	32631	24815	79686898
Treatment failure	30.32	18.89	16	32659	170470	79541243
Small intestinal obstruction	30.28	18.89	46	32629	27226	79684487
Cardio-respiratory arrest	29.75	18.89	105	32570	108405	79603308
Prothrombin level decreased	29.15	18.89	14	32661	1630	79710083
Embolism	28.79	18.89	32	32643	13950	79697763
Anxiety	28.46	18.89	36	32639	248476	79463237
Aspiration	28.27	18.89	38	32637	20120	79691593
Hospitalisation	27.97	18.89	3	32672	94233	79617480
Necrotising oesophagitis	27.70	18.89	12	32663	1101	79710612
Memory impairment	27.61	18.89	6	32669	111728	79599985
Venous thrombosis	27.43	18.89	23	32652	7093	79704620
Periorbital disorder	27.32	18.89	6	32669	51	79711662
Trichomegaly	27.10	18.89	7	32668	125	79711588
K-ras gene mutation	26.91	18.89	6	32669	55	79711658
Bronchitis	26.78	18.89	10	32665	130634	79581079
Hyperbilirubinaemia	26.72	18.89	41	32634	24477	79687236
Myelosuppression	26.52	18.89	54	32621	40242	79671471
Lymphopenia	26.40	18.89	46	32629	30511	79681202
Blood pressure decreased	26.20	18.89	95	32580	99371	79612342
Staphylococcal infection	26.02	18.89	67	32608	58228	79653485
Monocytopenia	25.59	18.89	7	32668	157	79711556
Osteoarthritis	25.36	18.89	3	32672	87306	79624407
Balance disorder	25.07	18.89	5	32670	98852	79612861
Product use in unapproved indication	24.97	18.89	40	32635	250319	79461394
Gastrooesophageal reflux disease	24.96	18.89	6	32669	104240	79607473
Pericarditis	24.96	18.89	6	32669	104230	79607483
Arthritis	24.92	18.89	8	32667	114872	79596841
Inappropriate schedule of product administration	24.57	18.89	12	32663	133616	79578097
Loss of personal independence in daily activities	24.37	18.89	6	32669	102574	79609139
Nail disorder	24.18	18.89	27	32648	11825	79699888
Induration	24.05	18.89	13	32662	1939	79709774
Overdose	24.02	18.89	24	32651	184182	79527531
Macular detachment	23.34	18.89	7	32668	220	79711493
Haemolytic uraemic syndrome	22.78	18.89	17	32658	4432	79707281
Carcinoembryonic antigen increased	22.55	18.89	13	32662	2196	79709517
Depression	22.22	18.89	34	32641	216756	79494957
Ileal perforation	22.12	18.89	10	32665	1015	79710698
Respiratory distress	21.98	18.89	63	32612	58276	79653437
Metastases to lymph nodes	21.76	18.89	24	32651	10373	79701340
Macular oedema	21.73	18.89	18	32657	5456	79706257
Abdominal pain	21.46	18.89	249	32426	389320	79322393
Nasal congestion	21.34	18.89	3	32672	76549	79635164
Respiratory failure	21.33	18.89	137	32538	180774	79530939
Abdominal compartment syndrome	20.70	18.89	11	32664	1586	79710127
Cardiac failure congestive	20.41	18.89	17	32658	142385	79569328
Hallucination	20.40	18.89	5	32670	85740	79625973
Wrong technique in product usage process	20.35	18.89	3	32672	73872	79637841
Nail toxicity	20.11	18.89	7	32668	356	79711357
Hypertrichosis	19.99	18.89	10	32665	1272	79710441
Tachycardia	19.97	18.89	133	32542	177635	79534078
Multiple-drug resistance	19.60	18.89	21	32654	8787	79702926
Eyelid oedema	19.50	18.89	26	32649	13661	79698052
Hypoaesthesia	19.49	18.89	27	32648	179325	79532388
Migraine	19.14	18.89	6	32669	87487	79624226
Asthenia	19.12	18.89	305	32370	511384	79200329
Acute respiratory distress syndrome	19.00	18.89	50	32625	44017	79667696
Pulse pressure decreased	18.90	18.89	7	32668	426	79711287

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FE01	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA MoA	N0000020010	HER1 Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
FDA EPC	N0000175664	Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Head and neck cancer	indication	255055008	DOID:11934
Squamous cell carcinoma of mouth	indication	307502000
Rectal cancer with wild-type RAS	indication	363351006	DOID:1993
Malignant tumor of colon	indication	363406005	DOID:219
Squamous cell carcinoma of larynx	indication	405822008
Squamous cell carcinoma of pharynx	indication	408649007
Squamous cell carcinoma of nose	indication	448930008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN	ANTIBODY BINDING	Kd	9.41		IUPHAR	DRUG LABEL

External reference:

ID	Source
D03455	KEGG_DRUG
4021419	VUID
N0000148833	NUI
4021419	VANDF
CHEMBL1201577	ChEMBL_ID
6882	IUPHAR_LIGAND_ID
DB00002	DRUGBANK_ID
318341	RXNORM
17947	MMSL
48970	MMSL
d05101	MMSL
008568	NDDF
409400001	SNOMEDCT_US
409401002	SNOMEDCT_US
C0995188	UMLSCUI
D000068818	MESH_DESCRIPTOR_UI
7906	INN_ID
85668777	PUBCHEM_CID
PQX0D8J21J	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-948	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-948	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-958	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections
ERBITUX	HUMAN PRESCRIPTION DRUG LABEL	1	66733-958	SOLUTION	2 mg	INTRAVENOUS	BLA	29 sections